CRINETICS PHARMACEUTIC

Crinetics Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference

18 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Presenting New Data from Open Label Extension Trial of Paltusotine in Acromegaly at the Society for Endocrinology BES Congress

08 Nov 2021 07:00:03 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

05 Nov 2021 07:00:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

25 Oct 2021 15:01:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock

21 Oct 2021 07:22:33 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

20 Oct 2021 15:01:37 By Nasdaq GlobeNewswire

Radionetics Oncology Emerges from Crinetics Pharmaceuticals with a Platform and Deep Pipeline of Nonpeptide Targeted Radiopharmaceutical Drug Candidates for Precision Oncology

18 Oct 2021 15:00:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Unveil its Parathyroid Hormone Receptor Antagonist Program at the American Society for Bone and Mineral Research Annual Meeting

27 Sep 2021 06:30:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals’ Oral SST5 Agonist CRN04777 Demonstrated Pharmacologic Proof-of-Concept with Strong Dose-dependent Suppression of Insulin Secretion in Phase 1 Single Ascending Dose Study

15 Sep 2021 15:01:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Participate in September Investor Conferences

07 Sep 2021 06:30:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Expands Executive Team with Addition of Jeff Knight as Chief Operating Officer

02 Sep 2021 06:30:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

10 Aug 2021 15:02:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals’ Oral ACTH Antagonist, CRN04894, Demonstrates Pharmacologic Proof-of-Concept with Dose-Dependent Cortisol Suppression in Single Ascending Dose Portion of Phase 1 Study

10 Aug 2021 15:01:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces $15.0 Million Private Placement with Frazier Healthcare Partners

29 Jul 2021 06:30:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Dosing of First Patient in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly

28 Jun 2021 06:30:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Appoints Garlan Adams as General Counsel

16 Jun 2021 07:30:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

06 May 2021 15:05:02 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Closing of Common Stock Offering

12 Apr 2021 15:05:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock

07 Apr 2021 17:31:23 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces 2021 Clinical Plans and Reports Fourth Quarter and Full Year 2020 Financial Results

30 Mar 2021 15:05:00 By Nasdaq GlobeNewswire